Distinct genetic clades of enterovirus D68 detected in 2010, 2013, and 2015 in Osaka City, Japan

Kaida, Atsushi; Iritani, Nobuhiro; Yamamoto, Seiji; Kanbayashi, Daiki; Hirai, Yuki; Togawa, Masao; Amo, Kiyoko; Kohdera, Urara; Nishigaki, Toshinori; Shiomi, Masashi; Asai, Sadasaburo; Kageyama, Tsutomu; Kubo, Hideyuki

doi:10.1371/journal.pone.0184335

Cited by 30 publications

(21 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Longitudinal surveillance in the same area showed the reemergence of EV-D68 in children with acute respiratory tract infections in 2013 and 2015. 20 The detection rate of EV-D68 among children was also higher than previous data from China in 2014. According to surveillance for enterovirus D68 data collected at a quaternary care children's hospital in Aurora, detection rate of EV-D68 from ICU patients' respiratory specimen increased from 0% in 2015 to 7.9% in 2016.…”

Section: Epidemiologymentioning

confidence: 63%

“…54 In Osaka City of Japan, EV-D68 detected in 2010, 2013 and 2015 belonged to clades C, A and B3, respectively. 20 The dominant strains of EV-D68 were clade B worldwide after 2014. 15,16,18,19,22 In Taiwan, the prevalent EV-D68 clades from 2007 to 2013 were A1, A2 and B1, and shifted to clade B3 after 2014.…”

Section: Discussionmentioning

confidence: 99%

“…The case numbers increased in November 2017. 23 There were Meijer et al 7 The Netherlands 1994e2010 57 0e89 y/o A&B Imamura et al 9 Philippines 2008e2009 21 1 me9 y/o Not mentioned Opanda et al 10 Kenya 2008e2011 13 2 me6 y/o A (84.6%) Lu et al 8 China 2009e2012 7 2 me10 y/o B&C 2 2 0 e51 y/o Huang et al 11 Taiwan 2007e2014 65 Not mentioned A&B Todd et al 12 New Zealand 2010 15 1 me48 y/o Not mentioned Levy et al 13 Australia 2008e2013 55 10 de81 y/o B Thongpan et al 14 Thailand 2012e2014 5 1e4 y/o B Messacar et al 15 The USA 2014 1153 3 de92 y/o B (92%) Skowronski et al 16 British Columbia 2014 146 0e90 y/o B (98%) Bragstad et al 17 Norway 2014 34 <15 y/o Not mentioned Schuffenecker et al 18 France 2014 178 3 de13.5 y/o B (88.6%) 22 17.2e99 y/o Carrion Martin et al 19 England 2014e2015 55 0e71 y/o B (85%) Kaida et al 20 Japan 2010e2015 18 <10 y/o C in 2010, A in 2013, B in 2015 Ruggieri et al 21 Argentina, 2016 11 3 me6 y/o Not mentioned Knoester et al 22 The Netherlands 2016 25 3 me70 y/o B Wei at al 23 Taiwan 2015e2017 51 2e13 y/o B few further cases of EV-D68 infection until November 2018 (Table 2). Focusing on the latest epidemiology in the United States, the New Vaccine Surveillance Network (NVSN) monitored the epidemic situation of EV-D68 among children with acute respiratory illness at 7 medical centers, and 358 (13.9%) of the total 2579 tested patients were confirmed to have EV-D68 infection in 2018.…”

Section: Epidemiologymentioning

confidence: 99%

See 2 more Smart Citations

Current status of enterovirus D68 worldwide and in Taiwan

Chang

2020

Pediatrics & Neonatology

View full text Add to dashboard Cite

Enterovirus D68 was first identified in 1962 and caused a worldwide outbreak starting from the North America in 2014. Enterovirus D68 has been in continuous circulation among many countries recently, including Taiwan. Reports also reveal high seroprevalence, which indicates that the disease burden of enterovirus D68 may be underestimated via viral culture or polymerase chain reaction results. Although most infected cases have mild respiratory illness, severe complications including acute flaccid myelitis and acute respiratory distress syndrome have also been reported. In the position of an emerging pathogen, enterovirus D68 poses a threat to public health and may cause devastating diseases. Diverse severity of neurological sequelae remains inevitable among acute flaccid myelitis patients, but no curable treatment is available currently. According to the management suggestions of the American Centers of Disease Control, uses of corticosteroids and plasmapheresis are either preferred or avoided and intravenous immunoglobulin also has no clear indication in the treatment for acute flaccid myelitis. In this review article, we provide information about the epidemiology, clinical recognition and treatment strategy of enterovirus D68. Better understanding of this disease is the foothold for advanced investigation and monitoring in the future.

show abstract

Section: Epidemiologymentioning

confidence: 63%

Section: Discussionmentioning

confidence: 99%

Section: Epidemiologymentioning

confidence: 99%

See 1 more Smart Citation

Current status of enterovirus D68 worldwide and in Taiwan

Chang

2020

Pediatrics & Neonatology

View full text Add to dashboard Cite

show abstract

“…In terms of the viral genome diversity, the sequence alignment and phylogenetic analysis revealed that all the 15 strains sequenced in this study belonged to B3 subclade. The EV-D68 strains circulating in 2015 in Hong Kong16 42 and its neighbouring region, Shenzhen,44 Taiwan district15 and Osaka45 have high similarity. Most of the EV-D68 strains identified in this region belong to B3 subclade (figure 2 and online supplementary table S2).…”

Section: Discussionmentioning

confidence: 99%

Molecular epidemiological study of enterovirus D68 in hospitalised children in Hong Kong in 2014–2015 and their complete coding sequences

et al. 2019

View full text Add to dashboard Cite

BackgroundHuman enterovirus D68 (EV-D68) was first isolated in 1962 and has aroused public concern recently because of a nationwide outbreak among children in 2014–2015 in the USA. The symptoms include fever, runny nose, sneezing, cough and muscle pains. It might be associated with severe respiratory illness in individuals with pre-existing respiratory conditions and its potential association with acute flaccid myelitis is under investigation. In Asia, EV-D68 cases have been reported in several countries.The studyWe aimed to understand the EV-D68 prevalence and their genetic diversity in Hong Kong children.MethodsA total of 10 695 nasopharyngeal aspirate (NPA) samples from hospitalised patients aged <18 years were collected from September 2014 to December 2015 in two regional hospitals. NPAs tested positive for enterovirus/rhinovirus (EV/RV) were selected for genotyping. For those identified as EV-D68, their complete coding sequences (CDSs) were obtained by Sanger sequencing. A maximum-likelihood phylogeny was constructed using all EV-D68 complete coding sequences available in GenBank (n=482).Results2662/10 695 (24.9%) were tested positive with EV/RV and 882/2662 (33.1%) were selected randomly and subjected to molecular classification. EV-D68 was detected in 15 (1.70%) samples from patients with clinical presentations ranging from wheezing to pneumonia and belonged to subclade B3. Eight CDSs were successfully obtained. A total of 10 amino acid residue polymorphisms were detected in the viral capsid proteins, proteases, ATPase and RNA polymerase.ConclusionB3 subclade was the only subclade found locally. Surveillance of EV-D68 raises public awareness and provides the information to determine the most relevant genotypes for vaccine development.

show abstract

“…Notably, children with a history of asthma or wheezing and adults with underlying diseases are more likely to develop severe EV-D68 infections [6,7]. EV-D68 was rst isolated from children with LRTIs in California in 1962, while the infection cases were rarely reported until an upsurge of cases has occurred during the last decade worldwide [1,[8][9][10][11][12]. Particularly, an outbreak in the United States in 2014 accounted for more than 1000 cases and 14 deaths of children [13].…”

Section: Introductionmentioning

confidence: 99%

Serological Study of Neutralizing Antibodies Against Enterovirus D68 Among Healthy Population in Xiamen, China

Cheng¹,

Lin²,

Zhu³

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Background: Enterovirus D68 (EV-D68) infections poses a serious public health threat, which caused outbreaks of severe respiratory illness and has been closely associated with "polio-like" central nervous system disease. The patterns of immune responses to EV-D68 have not been fully understood. This study was performed to investigate the level of neutralizing antibody against EV-D68 among the healthy population in Xiamen City.Methods: A total of 515 serum samples from healthy people were selected by stratified random sampling in Xiamen City in 2016, and the titer of neutralizing antibody against EV-D68 was detected by an efficient micro-neutralization assay.Results: The overall seroprevalence of neutralizing antibody against EV-D68 was 81.9%, and the overall geometric mean titers (GMT) was 248.0. The positive rates were 42.2%, 49.3%, 71.9%, 94.2% and 98.5%, respectively, in groups of <1, 1-3, 4-6, 7-19 and 20-39 years old, and were up to 100% in the 40-59 and ≥ 60 age groups. The GMTs in these seven groups were 1:39.8, 1:80.6, 1:133.2, 1:283.7, 1:253.3, 1:308.1 and 1:405.0, respectively. The seroprevalence and GMT of EV-D68 showed an increased trend with age, while gender and geographic area didn’t show significant impact.Conclusions: EV-D68 infection was prevalent in Xiamen City. Children are the high-risk groups for EV-D68-related illnesses, especially those aged ≤ 3 years. It is necessary to establish preventive measures and strengthened the surveillance on EV-D68 to prevent disease outbreaks.

show abstract

Distinct genetic clades of enterovirus D68 detected in 2010, 2013, and 2015 in Osaka City, Japan

Cited by 30 publications

References 32 publications

Current status of enterovirus D68 worldwide and in Taiwan

Current status of enterovirus D68 worldwide and in Taiwan

Molecular epidemiological study of enterovirus D68 in hospitalised children in Hong Kong in 2014–2015 and their complete coding sequences

Serological Study of Neutralizing Antibodies Against Enterovirus D68 Among Healthy Population in Xiamen, China

Contact Info

Product

Resources

About